Clinical trials: Cerebellar Diseases
Friedreich Ataxia
Safety and Efficacy of Etravirine in Friedreich Ataxia Patients
A drug repositioning effort provided evidence supporting the possible use of Etravirine, a drug approved for the treatment of HIV infections in patients starting from 2 years of age, as a treatment for FA.
- Trial name
- FAEST1 (NCT04273165)
- Testing
- Etravirine Tablets
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- IRCCS Eugenio Medea
Brain and Central Nervous System Tumors
SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors
RATIONALE: SCH 66336 may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of SCH 66336 in treating children with…
- Trial name
- NCT00015899
- Testing
- lonafarnib
- Where
- 9 sites in United States
- Volunteers
- 53 people
- Sponsor
- Pediatric Brain Tumor Consortium
Spinocerebellar Ataxia
The EUROSCA Natural History Study
The key goals of EUROSCA-NHS is to determine and compare the rate of disease progression in SCA1, SCA2, SCA3 and SCA6 including determination of the order and occurrence of non-ataxia symptoms, assessment of activities of daily…
- Trial name
- EUROSCA-NHS (NCT02440763)
- Where
- 16 sites in Austria, Belgium and 8 more
- Volunteers
- 400 people
- Sponsor
- Ataxia Study Group
Symptomatic Neurogenic Orthostatic Hypotension (NOH), Parkinson's Disease
Fipamezole in Neurogenic Orthostatic Hypotension
The purpose of this study is to determine whether Fipamezole is effective in the treatment of orthostatic hypotension and related symptoms in multiple system atrophy and Parkinson's disease.
- Conditions
- Symptomatic Neurogenic Orthostatic Hypotension (NOH), Parkinson's Disease, Multiple System Atrophy
- Trial name
- Foehn (NCT00758849)
- Testing
- Fipamezole
- Where
- 4 sites in France, Portugal
- Volunteers
- 24 people
- Sponsor
- Juvantia Pharma Ltd
Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
This phase I trial is studying the side effects and best dose of oxaliplatin when given together with irinotecan in treating young patients with refractory solid tumors or lymphomas.
- Conditions
- Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Diffuse Large Cell Lymphoma, Childhood Grade III Lymphomatoid Granulomatosis
- Trial name
- NCT00101270
- Testing
- irinotecan hydrochloride, oxaliplatin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Friedreich Ataxia
FRDA Investigator Initiated Study (IIS) With Elamipretide
To evaluate the safety, tolerability, and activity of Elamipretide in treating vision loss in Friedreich Ataxia (FRDA).
- Trial name
- ELViS-FA (NCT05168774)
- Testing
- Elamipretide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Children's Hospital of Philadelphia
Dystonia, Focal Dystonia
Brain Changes in Blepharospasm
This study will examine the role of certain areas of the brain in blepharospasm, a type of dystonia (abnormality of movement and muscle tone) that causes unwanted or uncontrollable blinking or closing of the eyelids.
- Conditions
- Dystonia, Focal Dystonia, Cerebellar Disease
- Trial name
- NCT00487383
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Spinocerebellar Ataxia Type 2
Clinical Trial With Riluzole in Spinocerebellar Ataxia Type 2 (ATRIL)
ATRIL is a multi-centric, double-blind randomized, two-arm controlled study. 42 SpinoCerebellar Ataxia type 2 (SCA2) patients, both gender, at least 18 years of age will be included.
- Trial name
- ATRIL (NCT03347344)
- Testing
- Riluzole
- Where
- France
- Volunteers
- 42 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Essential Tremor
Experimental Therapeutics in Essential Tremor Using Cerebellar Transcranial Direct Current Stimulation
The purpose of this study is to determine whether transcranial cathodal direct current stimulation (tDCS) delivered over the cerebellum can improve essential tremor.
- Trial name
- ELECTRE2 (NCT02052271)
- Testing
- Cathodal cerebellar transcranial direct current active stimulation
- Where
- France
- Volunteers
- 16 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Brain and Central Nervous System Tumors
Study of Tissue and Blood Samples From Patients With Low-Grade Glioma
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01004523
- Testing
- fluorescence in situ hybridization, loss of heterozygosity analysis, polymerase chain reaction
- Where
- 38 sites in United States
- Volunteers
- 135 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Stroke, Gait, Hemiplegic
Cerebellar rTMS to Improve Gait Recovery
The cerebellum is known to be strongly implicated in the functional reorganization of motor networks in stroke patients, especially for gait an balance functions.
- Trial name
- NCT03456362
- Testing
- REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- I.R.C.C.S. Fondazione Santa Lucia
Stroke, Transcranial Direct Current Stimulation
Hemodynamic Response of Anodal Transcranial Direct Current Stimulation Over the Cerebellar Hemisphere in Healthy Subjects
Upper extremity motor impairment is one of the major sequelae of stroke, resulting in limitation of activities of daily livings.
- Conditions
- Stroke, Transcranial Direct Current Stimulation, Functional Near Infrared Spectroscopy
- Trial name
- NCT04101695
- Testing
- tDCS
- Where
- South Korea
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Brain and Central Nervous System Tumors, Intraocular Melanoma
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 monoclonal antibody 3F8, can find tumor cells and carry tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin)
- Trial name
- NCT00445965
- Testing
- DNA analysis, immunologic technique, pharmacological study
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma
Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy
This phase II trial studies how well cilengitide works in treating younger patients with recurrent or progressive high-grade glioma that has not responded to standard therapy.
- Conditions
- Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma, Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Anaplastic Oligoastrocytoma
- Trial name
- NCT00679354
- Testing
- cilengitide, laboratory biomarker analysis, pharmacological study
- Where
- 20 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Paroxysmal Dyskinesia
Neural Correlates of Movement Disorders Associated With PRRT2 Related Paroxysmal Kinesigenic Dyskinesia - an Ancillary Study of AMEDYST Research
The main objective of this study is to investigate in real-time the neuronal correlates of paroxysmal dyskinesia episodes related to the PRRT2 mutation within this subgroup of patients (who can control paroxysmal dyskinesia…
- Trial name
- TRIGGER (NCT06701851)
- Testing
- Voluntary and involuntary conditions
- Where
- France
- Volunteers
- 1 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
SCA, Spinocerebellar Ataxias
Expanded Access Protocol of Troriluzole in Patients With Spinocerebellar Ataxia (SCA)
The purpose of this expanded access protocol is to provide access to the investigational drug troriluzole in patients with spinocerebellar ataxia (SCA).
- Trial name
- NCT06034886
- Testing
- Troriluzole
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Infratentorial Neoplasms, Mutism
Cerebellar Mutism Syndrome Study
The purpose of this study is to determine why up to 25% of the pediatric patients who have surgery for a tumor in the posterior fossa develops the Cerebellar Mutism Syndrome (CMS).
- Trial name
- NCT02300766
- Where
- 32 sites in Austria, Belgium and 12 more
- Volunteers
- 2,000 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Friedreich Ataxia
Iron-Chelating Therapy and Friedreich Ataxia
Friedreich ataxia, an autosomal recessive condition, ascribed to frataxin gene expansion, has been shown to result from an iron- induced injury to the mitochondrial respiratory chain.
- Trial name
- NCT00224640
- Testing
- Iron chelating intervention
- Where
- France
- Volunteers
- 15 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Schizophrenia, Autism Spectrum Disorder
Cerebellar Stimulation and Cognitive Control
The purpose of this study is to examine whether cerebellar stimulation can be used to improve cognitive deficits and mood in patients with schizophrenia, autism, bipolar disorder, Parkinson's disease, and major depression.
- Conditions
- Schizophrenia, Autism Spectrum Disorder, Bipolar Disorder, Depression
- Trial name
- NCT03217110
- Testing
- Repetitive Transcranial Magnetic Stimulation (rTMS)
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Krystal Parker, PhD
Cerebellar Cognitive-affective Syndrome
Validation of the Performance of the French Version of the Cerebellar Cognitive-Affective Syndrome Scale (CCASS) as a Screening Test for Cerebellar Cognitive-affective Syndrome: a National Multicenter Study
The primary objective of the study is to assess the performance of the French version of the Cerebellar Cognitive-Affective Syndrome Scale (CCASS) as a screening test for cerebellar cognitive-affective syndrome.
- Trial name
- CCASS-FR (NCT06005844)
- Testing
- Cerebellar Cognitive-Affective Syndrome Scale
- Where
- France
- Volunteers
- 217 people
- Sponsor
- Groupe Hospitalier de la Region de Mulhouse et Sud Alsace